Welcome to ...

LIVERPOOL 2012

The 58th Annual Meeting of the Scientific and Standardization Committee (SSC) of the ISTH starts in only two weeks! Months of careful programming and productive partnerships have resulted in a high quality, high value meeting experience that awaits attendees between June 27 and June 30.

The strong educational program at the front-end of the meeting will provide an opportunity for colleagues from around the world to learn about the latest advances in thrombosis and haemostasis. 19 SSC subcommittee sessions will provide unique opportunities for in-depth discussions in their respective scientific areas while reviewing the most current results of their ongoing projects and initiatives. The most challenging practical issues in thrombosis and hemostasis will be examined and partnerships will be developed to provide the best standards of care for patients.

SSC 2012 also debuts the use of a new ePoster technology. All participants and non-participating ISTH members can access these ePosters online during the meeting and at ePoster viewing stations. Discover the most recent achievements in basic science and clinical research through the results of the inaugural and highly successful Call for Abstracts. ePosters will also provide the basis for the Meet the Experts sessions that will allow for discussion of some of the most exciting scientific advances in an interactive environment.

Developing future leaders is a central theme to this year’s meeting. Join us for cross-disciplinary information exchange through engagements with external partners that provide the key to delivering solutions for patients with haemostatic and thrombotic problems.

Don’t forget the exciting social program as well! Take part (on the pitch or as a spectator) in the Football (Soccer) match (“Europe versus the World”) and the Party “…and the Beat goes on.”

ISTH Membership Elects Council Class of 2018

2012 is an election year for ISTH, and you as ISTH members selected the new Council members for the term 2012 – 2018. The Council is the governing body of the Society, and each Council election is extremely important to guarantee the continued success of our Society.

Over 38% of ISTH members have taken advantage of their privilege and responsibility to actively participate in this important democratic process. This represents one of the highest levels of participation in any ISTH Council election to date. ISTH is pleased to announce the newly-elected members of Council Class 2018:

continued on page 2 ››

continued on page 3 ››
Meet the experts

This popular and inspiring means of education will be made even more accessible. One format (on Wednesday afternoon) will celebrate the spirit of the late Mike Nesheim [discoverer of TAFI] who was always generous, down-to-earth and personable in disseminating knowledge. The second format, on Friday afternoon, will enhance our new ePoster experience, with Topic Experts leading and responding to new work in the field. Altogether, both formats will provide you with 18 Experts to Meet.

Sponsors

ISTH thanks its sponsors and partners for their generous support of SSC 2012.

Platinum > Bayer > Novo Nordisk

Gold > Inspiration Biopharmaceuticals

Silver > Pfizer > Stago

Bronze > Daiichi-Sankyo > Sanofi

Named lectures

- Shirley Johnson Memorial Lecture: Claire McLintock (New Zealand)
- Pia Glas-Greenwalt Memorial Lecture: Kenneth Kaushanky (USA)
- Marion Barnhart Memorial Lecture: Garret Fitzgerald (USA)
- Life Sciences Partners Award Lecture: Markus Huber-Lang (Germany)
- Kenneth Brinkhous Memorial Lecture: Denisa Wagner (USA)
- Arthur Bloom Lecture: Edward Tuddenham (UK)

ISTH bids farewell to the Council Class of 2012

As the new Council Class of 2018 takes office at the SSC 2012 in Liverpool, we also would like to specially recognize and thank the retiring Council members (Class of 2012).

Alan Nurden (France) and Bjarni Österud (Norway) have been very actively involved in the development of the Society over many years and specifically the last 6 years on Council. They led committees and spearheaded many important initiatives during their term. We are grateful for their dedication, leadership and guidance during their time as elected Councilors.

Michael Berndt (Ireland) and Henri Bounamaux (Switzerland) are also part of the Council Class of 2012. As per the Society’s Bylaws, Michael Berndt assumes a new leadership role as Chairman of Council (2012-2014), and Henri Bounamaux will remain an ex-officio Council member as the Immediate Past Chairman of Council.

Pieter Reitsma (the Netherlands) also continues on Council in his ex-officio role as Vice-President of the ISTH 2013 Amsterdam Congress.

We again thank all five Councilors for their time and service as we look forward to the continuing work of the Council with the active involvement of the newly elected Council Class of 2018.

ePosters

ePosters can be viewed in the exhibition hall on Wednesday-Friday from 10:00-17:00 and on Saturday from 10:00-13:00. On Friday, June 29, ePoster presentations will take place from 17:00-19:00. Be sure to stop by and take advantage of meeting the poster authors as well as experience this new technology! See the new eposter technology in action. (www.bit.ly/LdoI6E)
Message from the outgoing Council Chair

Dear ISTH members, dear colleagues and friends,

It seems like it was yesterday that I took over as Chair of the Council of ISTH two years ago in Cairo.

A lot has happened in the past 24 months, and I can say that I truly enjoyed this important leadership experience. It allowed me to experience many situations – exciting but also challenging – that have enriched my personal and professional life in a unique and profound way.

In looking back on my term, it is with great satisfaction to see the achievements and progress ISTH has made as the leading international Society in our field.

I don’t want to recount all of these because as active members you have been able to follow and experience many of them yourselves. Or you at least had a chance to read about them in this newsletter.

As gratifying as it may have been for me personally, it is important to always recognize that all of this is a team effort of many very dedicated and committed individuals. And it did not start 2 years ago but must be seen as a continuation of the most admirable work of my predecessors, Frits Rosendaal and Ian Peake.

I do want to express a special thanks, however, to my friends and colleagues who have served with me during my term as Council Chair and who have contributed so much to our field and our organization. I am always amazed how such busy and talented professionals are still able to dedicate so much of their energy and attention to advancing our field by volunteering their time through service to ISTH.

Another special recognition goes to the ISTH staff in our Office in Chapel Hill, but also to our editorial team in London and Aberdeen and the many other team members who contribute day in and day out to the success of our educational activities, meetings and congresses. They largely work in the background, but without their contributions, many of the activities and programs would not be as impactful as they are.

I had to face two distinct but totally different and highly demanding issues during my time as Council Chair: our 2011 Kyoto congress in the context of the Fukushima disaster, and the selection of the Executive Director, a new function at ISTH. The decisions made turned out to be very positive in both cases with a highly successful congress in Japan, masterfully organized by Dr. Ikeda and colleagues, and the choice of Tom Reiser as the first senior staff person of his kind in our Society. His impetus alongside the elected and appointed leaders of ISTH has initiated a move towards modernity in many aspects.

Thus, I leave the office of Chair of Council not only with a tremendous sense of pride and satisfaction, but also I leave it knowing that the state of the Society is strong and its future is bright. ISTH is in very capable hands. Indeed, I could not imagine a more talented group of professionals and persons as the custodians of our organization’s future.

Last but not least, I would like to thank all of you for your trust, loyalty and contributions as members of our organization and as active participants in the global exchange of knowledge and education in our field. Without you none of ISTH’s activities would be able to happen or would be meaningful.

I look forward to continued service to ISTH and to seeing most of you in Liverpool.

Best regards,

Henri Bounameaux
Chairman, ISTH Council

--- continued from cover ---

1. Peter Lenting (France)
2. Claire McLintock (New Zealand)
3. James Morrissey (USA)
4. Ingrid Pabinger (Austria)
5. Jeffrey Weitz (Canada)

The new Council members will take office at the conclusion of the 2012 SSC meeting in Liverpool and will assume important roles and responsibilities in leading ISTH and representing our Society’s members. Their terms will end at the Annual SSC Meeting in 2018.

ISTH would like to thank its members for the active participation in the Council election this year. We are delighted at the number of nominations and votes which shows the vibrancy and interest of our members in important Society matters.

The new Council class looks forward to joining the current Council members in the upcoming projects and initiatives of the Society. Plan to read the September ISTH newsletter to learn more about your new Council representatives and their ideas for ISTH and the global thrombosis and haemostasis field.
The Scientific and Standardization Committee (SSC) is pleased to announce the publication of the inaugural edition of a new series of clinical practice recommendations intended to provide “guidance” to practitioners. The first such guidance, “Duration of anticoagulant therapy after a first episode of unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH,” (www.bit.ly/JzvBT3) was published in the April 2012 issue of the Journal of Thrombosis and Haemostasis 10:698-702 and is also available on the ISTH web site (isth.org).

This document is a product of a collaboration of members of the SSC Guidance Committee. It is intended to provide an expert opinion on clinical conditions that present challenges to practitioners who manage patients with venous thromboembolism. As stated in the article, this guidance document, and those that will follow, does not present formal guidelines. Rather, SSC guidance articles are intended to offer the informed opinion of experienced SSC clinical investigators and clinicians on the management of clinical problems in haemostasis and thrombosis where alternative choices are complex, where limited randomized clinical trial data exists, and where guidelines provide no recommendations. These guidance articles will discuss factors that may influence decision-making by physicians and patients, and they may reflect on management considerations not yet incorporated into guidelines. They will be concise statements intended to be useful to practitioners.

Future articles on clinical guidance will cover a broad range of topics in haemostasis and thrombosis. They will be written by groups of experts organized by the SSC Subcommittee leadership. A formal proposal will be submitted by a Subcommittee Chairman to the SSC Guidance Committee for consideration. If approved, the article will be written and submitted to the Journal of Thrombosis and Haemostasis for external review prior to publication.

The SSC Guidance Committee welcomes suggestions for future guidance articles. If there is a topic for which you would like to see a guidance statement prepared, please contact Gerhard Johnson or other members of the Guidance Committee—Trevor Baglin, Kenneth Bauer, Harry Buller, James Douketis, Alok Srivastava—or a Chairman or Co-Chairman of a SSC Subcommittee.

The SSC Guidance Committee would be pleased to receive comments on the utility of the current guidance article and for suggestions of improvements that may be made in future publications. The intention of the SSC Guidance Committee is to produce useful clinical guidance documents. The ultimate judge of utility will be the members of ISTH. Please let us hear from you.

For more information, please contact Gerhard Johnson, Chairman, SSC Guidance Committee johns337@umn.edu
Novel oral anticoagulant drugs (NOACs) have been approved in many countries for a number of clinical indications such as the prevention of venous thromboembolism in patients undergoing major, elective orthopedic surgery; the prevention of stroke in patients with atrial fibrillation; and the treatment of deep vein thrombosis.

Despite their large use in some countries, there is limited information on their safety and efficacy in the real world after the positive results of phase III trials. Currently, only a few case reports of serious bleeding events have been published, but these reports do not help to understand their true incidence and provide little information about provoking risk factors and, most of all, the optimal management of these patients. A number of industry sponsored registries have been planned or are ongoing, but we are aware of few investigator-driven initiatives. Furthermore, there remain a number of practical issues which need to be better addressed, such as the laboratory monitoring of these new compounds when indicated and the correct reversal strategies.

The Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis is committed to the production of specific recommendations focusing on the management of patients starting on the NOACs, on the laboratory measurement of the NOACs, and on the use of reversal strategies. These recommendations are aimed at providing clinicians with practical suggestions based on the current knowledge of the pharmacology of these compounds and on the results of the few available studies.

The first recommendation will specifically focus on aspects related to patient selection, use of concomitant drugs, follow-up modalities, and monitoring of patient compliance. The second recommendation will discuss the potential role of tests that are readily available in most laboratories, and that could be easily performed for use in an emergency or urgent clinical scenario, as well as the role of quantitative tests that can be used to determine drug levels in non-urgent clinical scenarios. Finally, the third recommendation will focus on the procedures that should be applied for the management of patients with bleeding complications or requiring urgent invasive procedures.

Meanwhile, this Subcommittee has promoted two independent, collaborative studies on the determination of the anticoagulant effects of dabigatran and rivaroxaban. The first of the two projects was led by Job Harenberg and analyzed the anticoagulant effects of rivaroxaban on several coagulation tests using plasma samples spiked with the anticoagulant. This has been completed and is expected to be published soon as an official SSC communication. The second project, led by Elaine Gray, is currently underway. Future initiatives on other NOACs, such as apixaban or edoxaban, will soon be promoted.

Finally, the Subcommittee will promote a new, independent, investigator-driven registry on anticoagulant drugs. The Survey on Anticoagulated patients – Register (START SSC – ISTH) will be an international web-based registry that will gather information on baseline characteristics and long-term clinical outcome of patients treated with anticoagulant drugs. For each patient started on any anticoagulant treatment and with an intended treatment duration of at least 3 months, information will be collected on demographic data, indication to anticoagulant drug, type and dosing regimen of anticoagulant drug(s), concomitant therapies, comorbidities, clinical events during follow-up and clinical management (frequency of monitoring, use of laboratory tests, and so on). All included patients will be followed-up for a minimum of 1 year, independent of actual treatment duration.

With the participation of several centers worldwide we expect the enrollment of a large prospective cohort of patients treated for different indications. The registry will be chaired by a steering committee identified by the co-chairmen of this Subcommittee, and a national coordinator for each participating country will be identified. Data will be shared by all ISTH investigators, and will be separately available at each country level.

The registry, together with all other initiatives aimed to improve the knowledge on the NOACs, will be presented during the meeting in Liverpool on June 30th.

For more information, please contact

Walter Ageno
Chairman, SSC Subcommittee on Control of Anticoagulation
agewal@yahoo.com

Webcasts available now for 6th International Conference on Thrombosis and Hemostasis Issues in Cancer

The 6th Annual ICTHIC was held April 19-22, 2012 in Bergamo, Italy. Selected lectures are now freely accessible at www.informed-scientist.org.

The aim of ICTHIC is to review the recent advances in the understanding of the pathogenesis, prevention and treatment of thrombotic and hemorrhagic complications in cancer patients, both from the basic and clinical research points of view.

Plenary sessions include:

- Epidemiology and risk factors of venous thromboembolism
- Genomics and proteomics of the hemostatic system in cancer
- Bleeding complications in cancer patients
- Coagulation and cancer progress
- Hematological disorders
- Anticoagulants and cancer
- Platelets and vascular endothelium
- Prevention and treatment of thrombosis

For more on the successful 6th Annual ICTHIC, be sure to check out the meeting review article by Conference Chairman Anna Falanga in the September ISTH issue.
The Factor VIII & Factor IX SSC Subcommittee provides a forum for consideration of practical issues related to hemophilia and other rare bleeding disorders. In its continued efforts to provide state-of-the-art knowledge regarding the diagnosis and management of the disorders, this Subcommittee conducts projects which usually last for two years and aim to harmonize available laboratory evaluation and clinical care measures.

Finalized and reported projects

Seven projects started in 2009 and are going to be finished in 2012:
- Standardization of methods for performing the clot wave form analysis led by Dr. Midori Shima
- Potency labeling of clotting factor concentrates led by Dr. Anthony Hubbard
- Consensus definitions in haemophilia led by Dr. Victor Blanchette
- Pharmacokinetics led by Dr. Peter Collins
- Consensus definitions in rare bleeding disorders led by Dr. Flora Peyvandi
- Standardization of methods for performing the thromboelastogram led initially by Dr. Benny Sorensen and at present by Dr. Guy Young and Dr. Meera Chitlur
- Standardization of methods for performing the thrombin generation test led by Dr. Claude Negrier.

Achieved results of these projects are viewable as draft manuscripts on the ISTH Society website (http://www.isth.org/default/index.cfm/ssc1/subcommittees-working-groups) for further comments and discussion, except for “Consensus definitions in rare bleeding disorders.” This manuscript has been already submitted to the Journal of Thrombosis and Haemostasis.

Ongoing and new projects

Donna Di Michele is leading the project entitled “Clinical trial design for hemophilia” which started in 2011 and aims at determining the optimal prospective pre-licensure and observational post-licensure trial designs for new clotting factor concentrates for hemophilia patients. This group will present its first report at the SSC meeting in Liverpool.

Two projects are currently proposed and will hopefully be initiated in the near future:
- Bleeding score in hemophilia: a prognostic tool for clinical outcome led by Dr. Maria Elisa Mancuso and Dr. Alberto Tosetto aims to develop a user-friendly, validated clinical scoring system applicable to the hemophilia population in order to optimize the use of different treatment regimens and/or prevent clinical complications.
- Evaluation of hemostatic efficacy of novel FVIII / FIX concentrates and FVIII-inhibitor by-passing agents led by Dr. Andrew Lawrie and Dr.

Armando Tripodi will propose a bilateral approach to assess novel FVIII / FIX concentrates and FVIII-inhibitor bypassing agents using the thrombin generation and thromboelastography/thromboelastometry assays together with conventional therapeutic agents as a point of reference. Data from the assay of patients’ samples would be analyzed in conjunction with a clinical assessment of therapeutic efficacy.

The Subcommittee wishes to continue to provide researchers and clinicians with answers to practical challenges in the field, and highly welcomes innovative projects proposed by members of the Society.

A special acknowledgement goes to Alok Srivastava who critically evaluated most of the projects performed in the last three years and for his continuous support as well as all co-chairs of the Factor VIII & Factor IX SSC Subcommittee for their enthusiastic work.

For more information, comments, or to submit ideas for new projects, please contact

Flora Peyvandi
Chairman, Subcommittee on Factor VIII and IX
flora.peyvandi@unimi.it

Call for Comments: SSC Subcommittee on Factor VIII & IX

The SSC Subcommittee on Factor VIII and IX has issued a call for comments on a newly developed manuscript: “Measurement of factor VIII pharmacokinetics in routine clinical practice.” Please review the draft manuscript found here (www.bit.ly/LRZLOv) for a longer and more extensive overview at the various current projects of the Factor VIII and IX SSC subcommittee.

For more information, comments, or to submit ideas for new projects, please contact

Flora Peyvandi
Chairman, Subcommittee on Factor VIII and IX
flora.peyvandi@unimi.it

ISTH Reach-the-World Membership

Reduced fee memberships for researchers, educators and clinicians from the developing* countries.

In pursuit of its mission and recognizing that certain parts of the world have limited financial resources, the ISTH Reach-the-World Membership aims at allowing professionals from developing* countries to become actively involved and benefit from membership in our Society.

The membership fee for qualifying members is reduced to US $35.

ISTH Reach-the-World members have full membership privileges including online-only subscription to ISTH’s scientific journal JTH, may vote on Society matters, serve on Committees, enjoy members-only access to the website, as well as receive the ISTH e-Newsletter. ISTH RTW members also qualify for special discounts and eligibility for travel grants and other awards at ISTH meetings and congresses.

For more information on the program, eligibility criteria and to join, please visit: www.isth.org and go to “Membership” or contact the ISTH Office by email at headquarters@isth.org.

* countries designated as ‘developing’ by the classification of the World Bank.
Introduce a colleague to membership in ISTH!

ISTH and its activities around the world greatly depend on the active involvement of our members and the network of members around the world.

We invite your help and support as members of the Society to further expand ISTH’s initiatives, international community, reach and impact.

ISTH membership is of great value for researchers, clinicians, and medical professionals at all stages of their career. We encourage you to share the ISTH membership benefits with your colleagues and particularly highlight the 3 categories of membership:

- **Regular**: for fulltime professionals with a continuing scientific interest in thrombosis, hemostasis and vascular biology,
- **Associate**: students, trainees, postdocs, and nurses,
- **Reach the World**: researchers, educators and clinicians from the developing world.

ISTH membership offers very concrete benefits such as a personal subscription to JTH as well as opportunities for global networking and professional development. For more detailed information on each membership level, please visit the ISTH website (isth.org) and click on the “Membership” link.

2011 Mannucci Award Winners announced

The Mannucci Prizes are awarded in honor of Pier M. Mannucci, the first Editor-in-Chief of the *Journal of Thrombosis and Haemostasis*, for the best articles by Investigators younger than 35 years of age. The prizes are made possible by a generous contribution from Bayer Healthcare, and recipients are selected by a jury of editors. We congratulate the 2011 winners:


**Introduce a colleague to membership in ISTH!**

(www.bit.ly/KGEhVU)
Learn more about the benefits of your JTH online subscription and our partnership with Wiley Blackwell

One ISTH membership benefit includes access to the *Journal of Thrombosis and Haemostasis*. Through our publishing partnership with Wiley Blackwell, JTH is available on the Wiley Online Library, which houses over 5 million journal articles from 1,500 journals worldwide. Here are a few of the top reasons you should take advantage of this membership benefit:

- **You can...**
  - View articles on a range of topics in your subject area, some of which may include supplementary materials or reference linking for further analysis.
  - Read the latest State of the Art issue, a definitive collection of topical reviews in thrombosis and hemostasis written by internationally acclaimed experts in the field.
  - Sign up for e-alerts for up-to-the-minute updates from JTH and other relevant publications, for viewing on your computer or mobile devices.
  - Share and bookmark articles with social media, e-mail to a friend or export citation details.
  - View Society news and upcoming events.

**APRIL**

**Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH** (www.bit.ly/JzvBT3)

T. Baglin, K. Bauer, J. Douketis, H. Buller, A. Srivastava, G. Johnson

**From the JTH editors:**
The value of systematically developed evidence-based guidelines in the promotion and delivery of good medical care has been widely recognised. Among its membership the Society includes globally leading experts in a wide range of clinical and scientific areas. This places the Society in an excellent position to develop definitive opinions on a range of topics, under the auspices of the Scientific and Standardization Committee. The quality and utility of the documents can be further ensured through rigorous peer review prior to final acceptance for publication in the Journal of the Society. We are pleased that the first such clinical recommendation, on the duration of anticoagulation after a first episode of venous thromboembolism, has now been published in JTH. We fully expect this to be of great value to clinicians and to contribute to improved clinical management for the benefit of patients.

**A conceptual framework for two phases of anticoagulant treatment of venous thrombosis** (www.bit.ly/Jtdg5p)

C. Kearon

**MAY**

**In Focus Paper:** Diagnostic accuracy of magnetic resonance imaging for acute pulmonary embolism: results of the “IRM-EP” study (www.bit.ly/NaZSWU)

K. Sodhi and A. K. Saxena

**Commentary:** Magnetic resonance imaging for diagnosis of acute pulmonary embolism: Not yet a suitable alternative to CT-PA (www.bit.ly/Nb01Kb) M. V. Huisman, F. A. Klok

**In Focus Paper:** Factor Seven Activating Protease (FSAP): Does it Activate Factor VIII? (www.bit.ly/LFUJXX)


**Commentary:** FSAP: Does it do what it says on the tin? (www.bit.ly/KGAUhD) J. H. McVey

**In Focus Paper:** A high affinity, antidote-controllable prothrombin and thrombin-binding rna optamer inhibits thrombin generation and thrombin activity (www.bit.ly/KFpmLl)

K. M. Bompiani, D. M. Monroe, F. C. Church and B. A. Sullenger

**Commentary:** A Protease TAMER: A nucleic acid-based anticoagulant (www.bit.ly/JMf6ob) James C. Fredenburgh, Colin A. Kretz and Jeffrey I. Weitz

**In Focus Paper:** Single versus swarm detection of microparticles and exosomes by flow cytometry (www.bit.ly/M5mBqA)

E. van der Pol, M. J. C. Gemert, P. Harrison and C. Gardiner

**In Focus Paper:** Invisible vesicles swarm within the iceberg (www.bit.ly/LduN30) P. Harrison and C. Gardiner
ISTH is pleased to introduce the new members who have joined the Society's global network in the past three months, from February 14 2012 to May 15, 2012 (inclusive). We welcome you to the Society and look forward to your active engagement in 2012 and beyond!

### Get in touch!

To get in touch with our new members or other ISTH colleagues, please remember that the ISTH membership directory is available online in our members-only section at www.isth.org (log-in is required)! Simply open the pdf, print it or search it!

### ISTH Members benefit from 25% reduction on all Wiley-Blackwell books

Together with our partner, Wiley-Blackwell, publisher of ISTH’s journal JTH, ISTH is pleased to be able to offer to all members a special 25% discount on the entire book catalogue* (medical and non-medical) of Wiley Blackwell. To take advantage of this special discount, please log into the members-only section of the ISTH website (isth.org), click on the Wiley-Blackwell Book discount link and you will be redirected to the site of our publisher where you will be able to browse their books and apply your discount on any purchases.

We encourage you to take advantage of this ISTH membership benefit – it could mean significant savings for you!

---

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel</td>
<td>Abegunde</td>
<td>Lagos</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Paul</td>
<td>Batty</td>
<td>London</td>
<td>UK</td>
</tr>
<tr>
<td>Markus</td>
<td>Bender</td>
<td>Würzburg</td>
<td>Germany</td>
</tr>
<tr>
<td>Judith</td>
<td>Futtermenger</td>
<td>Mandurah</td>
<td>Australia</td>
</tr>
<tr>
<td>Lawrence</td>
<td>Gaul</td>
<td>Vail</td>
<td>USA</td>
</tr>
<tr>
<td>Adam</td>
<td>Giemczak</td>
<td>San Francisco</td>
<td>USA</td>
</tr>
<tr>
<td>Silvia</td>
<td>Grosso</td>
<td>Caba</td>
<td>Argentina</td>
</tr>
<tr>
<td>Edward</td>
<td>Hammitt</td>
<td>Durham</td>
<td>USA</td>
</tr>
<tr>
<td>Anggoro</td>
<td>Hartopo</td>
<td>Yogyakarta</td>
<td>Indonesia</td>
</tr>
<tr>
<td>Maria</td>
<td>Held</td>
<td>Halmstad</td>
<td>Sweden</td>
</tr>
<tr>
<td>Carola</td>
<td>Henriksson</td>
<td>Oslo</td>
<td>Norway</td>
</tr>
<tr>
<td>Anneliese</td>
<td>Hilger</td>
<td>Langen</td>
<td>Germany</td>
</tr>
<tr>
<td>Yu</td>
<td>Hu</td>
<td>Wuhan</td>
<td>China</td>
</tr>
<tr>
<td>Jamilja</td>
<td>Khizroeva</td>
<td>Moscow</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Michael</td>
<td>Kitt</td>
<td>Mountain View</td>
<td>USA</td>
</tr>
<tr>
<td>Vito</td>
<td>Laguarnaglia</td>
<td>Bari</td>
<td>Italy</td>
</tr>
<tr>
<td>Jacqueline</td>
<td>Lim</td>
<td>Singapore</td>
<td>Singapore</td>
</tr>
<tr>
<td>Yaliz</td>
<td>Loperena</td>
<td>Bayamon</td>
<td>Puerto Rico</td>
</tr>
<tr>
<td>Ehab</td>
<td>Mady</td>
<td>Newport Beach</td>
<td>USA</td>
</tr>
<tr>
<td>Natalia</td>
<td>Makatsariya</td>
<td>Moscow</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>James</td>
<td>McFadyen</td>
<td>Melbourne</td>
<td>Australia</td>
</tr>
<tr>
<td>Sylvia</td>
<td>Nuernberg</td>
<td>Amsterdam</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Ioana</td>
<td>Olteanu</td>
<td>Leipzig</td>
<td>Germany</td>
</tr>
<tr>
<td>Hans-Martin</td>
<td>Otten</td>
<td>Amsterdam</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Martin</td>
<td>Palmeri</td>
<td>Piney Flats</td>
<td>USA</td>
</tr>
<tr>
<td>Nathalie</td>
<td>Pequeriaux</td>
<td>Hertogenbosch</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Marika</td>
<td>Pikta</td>
<td>Tallinn</td>
<td>Estonia</td>
</tr>
<tr>
<td>Jayne</td>
<td>Prats</td>
<td>Carlisle</td>
<td>USA</td>
</tr>
<tr>
<td>Dana</td>
<td>Provaznikova</td>
<td>Prague</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Adriano</td>
<td>Reis</td>
<td>Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>Tyler</td>
<td>Smith</td>
<td>Vancouver</td>
<td>Canada</td>
</tr>
<tr>
<td>Kartikki</td>
<td>Thakur</td>
<td>Clwyd, Saltney</td>
<td>UK</td>
</tr>
<tr>
<td>Eric</td>
<td>Tse</td>
<td>Hong Kong</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Claire</td>
<td>Whyte</td>
<td>Aberdeen</td>
<td>UK</td>
</tr>
<tr>
<td>Erik</td>
<td>Beckers</td>
<td>Cadier en Keer</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Paolo</td>
<td>Bucciarelli</td>
<td>Milan</td>
<td>Italy</td>
</tr>
<tr>
<td>Karl</td>
<td>Desch</td>
<td>Ann Arbor</td>
<td>USA</td>
</tr>
<tr>
<td>Bruno</td>
<td>Duarte</td>
<td>Valinhos</td>
<td>Brazil</td>
</tr>
<tr>
<td>Telma</td>
<td>Gadelha</td>
<td>Rio de Janeiro</td>
<td>Brazil</td>
</tr>
<tr>
<td>Maged</td>
<td>Gharib</td>
<td>Prescot</td>
<td>UK</td>
</tr>
<tr>
<td>Nelson</td>
<td>Hammerschlag</td>
<td>Sao Paulo</td>
<td>Brazil</td>
</tr>
<tr>
<td>Nicola</td>
<td>Hurst</td>
<td>Adelaide</td>
<td>Australia</td>
</tr>
<tr>
<td>Eui-seong</td>
<td>Hwang</td>
<td>Concord</td>
<td>USA</td>
</tr>
<tr>
<td>Marianne</td>
<td>Landau</td>
<td>Rio de Janeiro</td>
<td>Brazil</td>
</tr>
<tr>
<td>Lilley</td>
<td>Leong</td>
<td>San Francisco</td>
<td>USA</td>
</tr>
<tr>
<td>Marco</td>
<td>Marietta</td>
<td>Modena</td>
<td>Italy</td>
</tr>
<tr>
<td>Maria</td>
<td>Martins</td>
<td>Belo Horizonte Minas Gerais</td>
<td>Brazil</td>
</tr>
<tr>
<td>Fermina</td>
<td>Mazzella</td>
<td>Staten Island</td>
<td>USA</td>
</tr>
<tr>
<td>Vânia</td>
<td>Morelli</td>
<td>Botucatu</td>
<td>Brazil</td>
</tr>
<tr>
<td>Gregory</td>
<td>Pollack</td>
<td>Asheville</td>
<td>USA</td>
</tr>
<tr>
<td>Juan</td>
<td>Reyes Herrera</td>
<td>Mexico City</td>
<td>Mexico</td>
</tr>
<tr>
<td>Rosângela</td>
<td>Ribeiro</td>
<td>Fortaleza</td>
<td>Brazil</td>
</tr>
<tr>
<td>Françoise</td>
<td>Rossi</td>
<td>Courtaboeuf</td>
<td>France</td>
</tr>
<tr>
<td>Atsuo</td>
<td>Tomioka</td>
<td>Kobe</td>
<td>Japan</td>
</tr>
<tr>
<td>Cecília</td>
<td>Vasconcelos</td>
<td>Curitiba</td>
<td>Brazil</td>
</tr>
</tbody>
</table>
Mayo Clinic’s 4th Coagulation Testing Quality Conference will provide a unique international forum for communication and discussion of current quality issues of coagulation laboratory testing. This 2.5 day Conference will again feature presentations by internationally renowned experts, followed by faculty question-and-answer discussions with the audience, as well as including scientific abstract presentations (oral and poster). Four Breakfast-with-the-Experts sessions this year will focus on case presentation discussions.

New for this year, Mayo Clinic’s 10th Coagulation Wet Workshop is an optional one-day educational event preceding the Conference. Both the Conference and the Wet Workshop will cover a wide range of topics focused on laboratory quality-related issues including, but not limited to, external quality assurance programs, quality control, proficiency testing, testing guidelines and recommendations, inspections and accreditations, various issues of common and esoteric coagulation tests and disorders, anticoagulant and anti-platelet treatment monitoring, and recent advances in coagulation laboratory testing.

The Conference and Wet Workshop will be held adjacent to the main Mayo Clinic campus in Rochester, MN, USA. For more information, please visit here (http://bit.ly/KRI84e) or the meeting website found here: http://www.mayomedicallaboratories.com/education/coag2012
ISTH Mission

The International Society on Thrombosis & Haemostasis (ISTH) is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH is an international professional individual membership organization with over 3,000 members in more than 80 countries around the world.

Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and conferences, peer-reviewed publications and expert committees.

Contact info

International Society on Thrombosis and Haemostasis
610 Jones Ferry Rd, Suite 205
Carrboro, NC 27510, USA

Phone: +1 919 929 3807
Fax: +1 919 929 3935
Email: headquarters@isth.org
www.isth.org

design by www.adrialdesigns.com

ISTH Council

Chair of Council (2010-2012)
Henri Bounameaux, Switzerland

Secretary/Chair-Elect (2010-2012/2012-2014)
Michael Berndt, Ireland

Treasurer (2011-2015)
Nuala Booth, UK

Class of 2012
Michael Berndt, Ireland
Henri Bounameaux, Switzerland
Alan Nurden, France
Bjarne Østerud, Norway
Pieter Reitsma, The Netherlands

Class of 2014
Nuala Booth, UK
Francoise Dignat-George, France
Nigel Key, USA
Robert Montgomery, USA
Hugo ten Cate, The Netherlands

Class of 2016
Marco Cattaneo, Italy
Björn Dahlbäck, Sweden
Andreas Greinacher, Germany
Paula Tracy, USA
Yukio Ozaki, Japan

EX-OFFICIO COUNCIL MEMBERS

Secretary General (2010-2014)
Bruce Furie, USA

President of the XXIV Congress (Amsterdam, 2013) & Immediate Past Chair (of Council)
Frits R. Rosendaal, The Netherlands

Vice-President of the XXIV (Amsterdam, 2013) Congress
Pieter Reitsma, The Netherlands

Past President of XXIII Congress (Kyoto 2011)
Yasuo Ikeda, Japan

Editors-in-Chief, Journal of Thrombosis and Haemostasis
Mike Greaves and David Lane, UK

Chairman, Scientific and Standardization Committee
Anna Falanga, Italy

Copyright

ISTH makes available this Newsletter for the benefit of our members and to promote research and learning in the field. Unless otherwise restricted by notice on a particular page, the following terms of use apply. Permitted uses: These materials may be downloaded and reproduced by our members for their personal use, for reference in their own research, and for the educational and research use of students whom they are teaching in a nonprofit educational institution. Requirements for use: When use is permitted, the author(s) of the material must be credited, all copyright notices must be reproduced, and the following credit line must be given: Used with permission from ISTH, www.isth.org. All copyrights reserved. All other proposed uses require the specific written permission of ISTH. ISTH reserves the right to review uses of these materials to ensure compliance with its policies, and the right to revoke permission for use, for any reason. Publication copyright © International Society on Thrombosis and Haemostasis 2012.
2013
NETHERLANDS

XXIVTH CONGRESS
OF THE INTERNATIONAL
SOCIETY ON THROMBOSIS
AND HAEMOSTASIS

JUNE 29 - JULY 4
Amsterdam, The Netherlands

www.isth2013.org

DON’T MISS IT!!